# Phase I Clinical Study of ZL-82 Tablets

> **NCT06055023** · PHASE1 · COMPLETED · sponsor: **Chengdu Zenitar Biomedical Technology Co., Ltd** · enrollment: 69 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)
- Inflammatory Bowel Disease - IBD1

## Interventions

- **DRUG:** ZL-82 12.5mg
- **DRUG:** ZL-82 25mg
- **DRUG:** ZL-82 50mg
- **DRUG:** ZL-82 100mg
- **DRUG:** ZL-82 200mg
- **DRUG:** ZL-82 300mg
- **DRUG:** ZL-82 450mg
- **DRUG:** ZL-82 600mg
- **DRUG:** zL-82 placebo 12.5mg
- **DRUG:** ZL-82 placebo 25mg
- **DRUG:** ZL-82 placebo 50mg
- **DRUG:** ZL-82 placebo 100mg
- **DRUG:** ZL-82 placebo 200mg
- **DRUG:** ZL-82 placebo 300mg
- **DRUG:** ZL-82 placebo 450mg
- **DRUG:** ZL-82 placebo 600mg

## Key facts

- **NCT ID:** NCT06055023
- **Lead sponsor:** Chengdu Zenitar Biomedical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-09
- **Primary completion:** 2024-01-28
- **Final completion:** 2024-06-13
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06055023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06055023, "Phase I Clinical Study of ZL-82 Tablets". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06055023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*